News Archive

June 2020

• Press Release Jun 26, 2020

  Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

  If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-…
• Key Release Jun 25, 2020

  Novartis Resolves Legacy FCPA Investigations

  Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA)…
• Press Release Jun 25, 2020

  Novartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis

  The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from…
• Featured News Jun 24, 2020

  Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19

  Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.

• Press Release Jun 24, 2020

  Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

  83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago 86% of tech professionals agree: the…
• In The News Jun 23, 2020

  Breaking Through The Glass Ceiling - A Spring For Women In Artificial Intelligence

• In The News Jun 22, 2020

  The Curious Advantage: Curiosity – The CEO and The Chief People and Organization Officer Perspective

  Vas Narasimhan, CEO of Novartis and Steven Baert, Novartis’ Chief People and Organization Officer join the authors of The Curious Advantage Simon Brown, Paul Ashcroft and Garrick Jones, to…
• Press Release Jun 19, 2020

  Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

  Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
• 
  Story Jun 18, 2020 Access to Healthcare

  Streamlining systems to respond to COVID-19

  Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.

• Featured News Jun 18, 2020

  World Sickle Cell Day 2020

  Standing by people with sickle cell disease and their families

• Press Release Jun 18, 2020

  Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania

  New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients…
• Key Release Jun 17, 2020

  Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

  FDA approval for Cosentyx® is based on the Phase III PREVENT trial,  demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial…